Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Receivables (2020 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Change in Receivables for 6 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 241.11% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, up 105.13% year-over-year, with the annual reading at $6.4 million for FY2025, 105.13% up from the prior year.
  • Change in Receivables hit -$1.3 million in Q4 2025 for Eton Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $11.0 million in Q1 2025 to a low of -$4.7 million in Q1 2022.
  • Historically, Change in Receivables has averaged $643850.0 across 5 years, with a median of $303000.0 in 2021.
  • Biggest five-year swings in Change in Receivables: soared 10495.83% in 2021 and later plummeted 1955.16% in 2022.
  • Year by year, Change in Receivables stood at $5.1 million in 2021, then tumbled by 93.04% to $354000.0 in 2022, then plummeted by 123.73% to -$84000.0 in 2023, then surged by 1217.86% to $939000.0 in 2024, then crashed by 241.11% to -$1.3 million in 2025.
  • Business Quant data shows Change in Receivables for ETON at -$1.3 million in Q4 2025, -$1.4 million in Q3 2025, and -$1.9 million in Q2 2025.